中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01177 中国生物制药

休市中 04-24 16:08:27

5.680

+0.090

+1.61%

最高5.690	最低5.470	成交量8,366万
今开5.550	昨收5.590	日振幅3.94%
总市值1,065亿	流通市值1,065亿	总股本187.45亿
成交额4.70亿	换手率0.45%	流通股本187.45亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01177","market":"HK","secType":"STK","nameCN":"中国生物制药","latestPrice":5.68,"timestamp":1777018107003,"preClose":5.59,"halted":0,"volume":83659927,"delay":0,"changeRate":0.01610017889087654,"floatShares":18745000000,"shares":18745000000,"eps":0.14877264286273956,"marketStatus":"休市中","change":0.09,"latestTime":"04-24 16:08:27","open":5.55,"high":5.69,"low":5.47,"amount":469703434,"amplitude":0.039356,"askPrice":5.68,"askSize":434000,"bidPrice":5.67,"bidSize":48000,"shortable":3,"etf":0,"ttmEps":0.14877264286273956,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":7,"adr":0,"listingDate":1070812800000,"exchange":"SEHK","adjPreClose":5.59,"dividendRate":0.018176,"openAndCloseTimeList":[[1776994200000,1777003200000],[1777006800000,1777017600000]],"volumeRatio":1.2486315226878872,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"SBO.HK","impliedVol":0.3646,"impliedVolPercentile":0.2154},"requestUrl":"/m/hq/s/01177","defaultTab":"news","newsList":[{"id":"1135919559","title":"中国生物制药：4月24日回购178万股，耗资约1008.90万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135919559","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135919559?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:04","pubTimestamp":1777021444,"startTime":"0","endTime":"0","summary":"中国生物制药（股票代码：01177）于2026年4月24日进行股份回购，涉及178万股普通股，占公司已发行股本约0.009%。每股回购价介乎5.65港元至5.69港元，总金额约1008.90万港元。\n公告显示，公司于上述回购完成后，已发行股本仍为18,745,367,230股。根据2025年6月10日通过的购回授权，公司可回购股份总数为1,876,071,723股，截至目前已累计回购22,380,000股。公司方面确认本次回购符合相关上市规则及法例要求。\n本公告由公司秘书赖娟签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药：4月24日回购178万股，耗资约1008.90万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629361811","title":"中国生物制药(01177)4月24日斥资1008.9万港元回购178万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629361811","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629361811?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:01","pubTimestamp":1777021273,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年4月24日该公司斥资1008.9万港元回购178万股，回购价格为每股5.65-5.69港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433400.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK1191","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1515","BK1589","01177","IE00BZ08YR35.GBP","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182441065","title":"中国生物制药4月23日回购180万股股份，涉资约1,005.48万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1182441065","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182441065?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:47","pubTimestamp":1776934047,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年4月23日发布公告，披露当日在香港联交所回购180万股普通股份，占已发行股本约0.01%。本次回购价格介乎每股5.58港元至5.60港元，总涉资约1,005.48万港元。公告显示，回购完成后，公司已发行股本仍为18,745,367,230股，库藏股数量保持为0股。截至公告日，累计已回购股份数为20,600,000股，占回购授权决议通过当日公司已发行股本的约0.11%。公司确认已遵守香港联合交易所有限公司的相关上市规则及法定程序，公告由公司秘书赖娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药4月23日回购180万股股份，涉资约1,005.48万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101961182","title":"中国生物制药4月22日回购172万股，涉资约1,002.38万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101961182","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101961182?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:27","pubTimestamp":1776850068,"startTime":"0","endTime":"0","summary":"2026年4月22日，中国生物制药公告显示，公司于当日于香港联交所场内回购1,720,000股普通股，占已发行股本约0.009%。本次回购每股价格介乎5.82港元至5.84港元，总金额约10,023,816港元，折合约1,002.38万港元。本次回购根据2025年6月10日通过的购回授权进行，授权可回购股份总数为1,876,071,723股，截至目前已累计回购18,800,000股，占授权通过当日已发行股本约0.1%。公司确认上述回购行为已遵守香港联合交易所有限公司证券上市规则及相关法律法规。公告由公司秘书赖娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药4月22日回购172万股，涉资约1,002.38万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629199710","title":"中国生物制药(01177)4月22日斥资1002.38万港元回购172万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629199710","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629199710?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:22","pubTimestamp":1776849734,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年4月22日该公司斥资1002.38万港元回购172万股，回购价格为每股5.82-5.84港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","IE00BZ08YS42.EUR","BK1521","BK1515","01177","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1589","IE00BZ08YT58.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629067858","title":"中国生物制药附属自主研发LM-364、LM-338公布研究数据，计划2026年启动首次人体试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2629067858","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629067858?lang=zh_cn&edition=full","pubTime":"2026-04-22 09:05","pubTimestamp":1776819900,"startTime":"0","endTime":"0","summary":"4月22日，中国生物制药（01177）发布公告，旗下全资附属公司礼新医药科技（上海）有限公司自主研发的两款新一代抗体偶联药物LM-364和LM-338，于2026年美国癌症研究协会年会公布最新研究数据。LM-364针对肿瘤微环境中的Nectin-4靶点，显示出在高浓度ANP条件下的优越药物内化与毒素释放能力，显著降低对正常组织的毒性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713432933.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","IE00BZ08YS42.EUR","BK1589","BK1191","IE00BZ08YT58.USD","01177","HK0000165453.HKD","IE00BZ08YR35.GBP","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629906669","title":"中国生物制药(01177)：礼新医药于AACR 2026公布两款ADC最新研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629906669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629906669?lang=zh_cn&edition=full","pubTime":"2026-04-22 06:16","pubTimestamp":1776809789,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 公布，该集团全资附属公司礼新医药科技(上海)有限公司自主研发的两款新一代抗体偶联药物 LM-364 “Nectin-4TME ADC”及LM-338 “STn ADC”，于2026年美国癌症研究协会年会公布最新研究数据。LM-364是礼新医药依托自主开发的肿瘤微环境平台开发的新一代Nectin-4TME ADC。目前，LM-364已向美国食品药品监督管理局递交新药临床试验申请，计划于2026年启动首次人体临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","IE00BZ08YT58.USD","IE00BZ08YR35.GBP","BK1574","01177","BK1191","BK4231","IE00BZ08YS42.EUR","159938","BK4080","09939","BK1161","BK1521","ADC","BK1515","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114469052","title":"中国生物制药：4月21日回购173.00万股，耗资约1,006.08万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1114469052","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114469052?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:11","pubTimestamp":1776762710,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司于2026年4月21日公告，该公司当日于香港联交所场内回购普通股，共涉及1,730,000股，约占已发行股本的0.009%。此次回购每股价格介乎港币5.81元至5.83元，总耗资约港币10,060,815元。本次回购完成后，公司已发行股本仍为18,745,367,230股，库存股份数量维持为0股。根据公告，上述回购股份目前尚未注销。截至本次回购前，公司累计已回购17,080,000股，占该授权总数约0.091%。公告同时确认，本次回购活动符合香港联合交易所有限公司证券上市规则的相关规定。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"中国生物制药：4月21日回购173.00万股，耗资约1,006.08万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629081995","title":"中国生物制药(01177)4月21日斥资1006.08万港元回购173万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629081995","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629081995?lang=zh_cn&edition=full","pubTime":"2026-04-21 17:08","pubTimestamp":1776762519,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年4月21日斥资1006.08万港元回购173万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01177","IE00BZ08YR35.GBP","BK1521","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00BZ08YT58.USD","BK1515","BK1589","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628743751","title":"中国生物制药(01177)：贝莫苏拜单抗联合安罗替尼治疗腺泡状软组织肉瘤新适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2628743751","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628743751?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:53","pubTimestamp":1776675224,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主开发的国家1类创新药贝莫苏拜单抗联合安罗替尼已获得中国国家药品监督管理局的上市批准，用于治疗晚期或不可切除腺泡状软组织肉瘤。贝莫苏拜单抗是一款全新序列的创新人源化抗PD-L1单抗，此次是其获批上市的第5项适应症。在此基础上，贝莫苏拜单抗联合安罗替尼疗法的成功获批，将为此类患者带来一种新的治疗选择。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430679.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","IE00BZ08YR35.GBP","BK1515","BK1521","IPOS","IE00BZ08YT58.USD","01177","BK1589","BK1191","IE00BZ08YS42.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181513005","title":"中国生物制药创新药组合获批 贝美司托巴联合安罗替尼获NMPA批准用于晚期肺泡软组织肉瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1181513005","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181513005?lang=zh_cn&edition=full","pubTime":"2026-04-20 16:53","pubTimestamp":1776675195,"startTime":"0","endTime":"0","summary":"中国生物制药宣布，其创新药贝美司托巴（Benmelstobart）与安罗替尼（Anlotinib）联合疗法已正式获得国家药品监督管理局（NMPA）批准，用于治疗晚期肺泡软组织肉瘤（ASPS）。\n这一批准标志着该联合疗法在中国首次获批用于这一罕见恶性肿瘤。肺泡软组织肉瘤是一种进展缓慢但易转移的软组织肉瘤亚型，目前临床治疗选择有限。\n贝美司托巴作为新型小分子免疫调节剂，与多靶点酪氨酸激酶抑制剂安罗替尼的联合使用，在临床试验中展现出协同抗肿瘤活性。此次获批将为晚期肺泡软组织肉瘤患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00BZ08YS42.EUR","BK1589","IE00BZ08YT58.USD","BK1521","HK0000165453.HKD","BK1515","IE00BZ08YR35.GBP","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628569761","title":"中国生物制药(01177)：礼新医药于AACR 2026公布MK-2010/LM-299初步临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2628569761","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628569761?lang=zh_cn&edition=full","pubTime":"2026-04-19 18:10","pubTimestamp":1776593401,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，本集团全资附属公司礼新医药科技(上海)有限公司自主研发的创新药MK-2010/LM-299“PD-1/ VEGF双 抗 ”于 2026年美国癌症研究协会年会公布初步临床数据。MK-2010/LM-299是一款在研的四价双特异性抗体，同时靶向程序性细胞死亡蛋白-1 及血管内皮生长因子，其采用IgG-VHH融合结构并具有Fcγ沉默功能。无论是通过联合给药还是双特异性抗体，基于PD-1抑制联合VEGF阻断的治疗策略已在多种晚期实体瘤中显示出临床疗效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01177","IE00BZ08YS42.EUR","BK1589","IE00BZ08YT58.USD","BK1161","BK1521","IE00BZ08YR35.GBP","159938","BK1515","09939","BK1191","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101995964","title":"中国生物制药：4月16日回购1,535.00万股，耗资约8,986.20万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101995964","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101995964?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:15","pubTimestamp":1776327341,"startTime":"0","endTime":"0","summary":"中国生物制药有限公司（01177）于2026年4月16日公告回购股份，回购数量计1,535.00万股，占当日前已发行股份约0.082%。公司披露的回购均价为每股约5.8542港元，总涉资约8,986.20万港元。\n本次股份回购完成后，公司已发行股本由18,760,717,230股下降至18,745,367,230股。公司同时确认已遵守香港联合交易所有限公司证券上市规则及相关法例的规定。公告由公司秘书赖娟签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627260236","title":"中国生物制药(01177)注销1535万股已回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2627260236","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627260236?lang=zh_cn&edition=full","pubTime":"2026-04-16 16:14","pubTimestamp":1776327242,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药(01177)发布公告，于2026年4月16日，该公司注销1535万股已回购股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429340.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","BK1589","IE00BZ08YR35.GBP","BK1515","IE00BZ08YS42.EUR","BK1191","01177","IE00BZ08YT58.USD","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627254292","title":"港股公告掘金 | 宁德时代一季度归母净利润207.38亿元 同比增长48.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627254292","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627254292?lang=zh_cn&edition=full","pubTime":"2026-04-16 09:01","pubTimestamp":1776301266,"startTime":"0","endTime":"0","summary":"【重大事项】宁德时代(03750)拟投资 300 亿元设立全资子公司 打造新能源矿产平台美格智能(03268)拟投资3亿元于AI研发及先进制造产业项目并签署投资协议力勤资源(02245)：印尼镍矿政策变动不影响正常经营 与合作伙伴保持良好合作关系确保Obi项目稳定运行中远海能(01138)拟10.18亿元建造两艘巴拿马型原油轮荣昌生物(09995)：收到艾伯维就RC148独家授权许可协议支付的6.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"05d74946e1a2924d42dd26ed36b9a988","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00670","LU2125910849.SGD","LU1105468828.SGD","LU2152927971.USD","LU0516422366.SGD","IE00B5MMRT66.SGD","LU2125910500.SGD","SG9999001903.USD","LU0164872284.USD","LU2506952410.USD","SGXZ49509284.SGD","LU1102505929.USD","EVS.SI","300750","LU1039395188.USD","LU0456846285.SGD","02298","LU2097828631.EUR","BK1575","SG9999001846.SGD","LU0540923850.HKD","LU1720050803.USD","LU0107464264.USD","IE00B8L5B284.USD","LU0979878070.USD","BK1166","LU0326948709.USD","SBHMY","LU0359201612.USD","HXXD.SI","LU1969619763.USD","IE00B8HQ1Z84.USD","IE00BD6J9T35.USD","LU0456827905.SGD","LU1064131003.USD","08279","LU0650527681.SGD","02556","IE0034224299.USD","LU1051768304.USD","LU0359202008.SGD","LU0823039010.USD","LU0188438112.USD","LU2348773727.SGD","LU1048596156.SGD","LU0348816934.USD","LU0328353924.USD","LU0143863784.USD","02465","LU0611395673.USD","LU0348805143.USD","LU0516423091.SGD","LU0348814723.USD","LU0594300179.USD","LU1323998911.USD","LU0259732245.USD","LU2360107325.USD","600026","LU0823397103.USD","LU2294711713.HKD","02038","LU2580892789.USD","002881","00300","CCOZY","LU0672654166.SGD","LU1146622755.USD","603906","LU0039217434.USD","LU2226246903.HKD","LU0251143458.SGD","LU0261950470.USD","LU0607220059.USD","BK1116","BK0224","LU0307460666.USD","LU0047713382.USD","LU2476274308.USD","BK4526","LU0011963245.USD","601898","02245","LU0128522157.USD","LU3063872942.SGD","FXCNY","LU0823437842.USD","LU0823038988.USD","LU0051755006.USD","LU1580142542.USD","LU2298322129.HKD","LU0348827113.USD","LU0823040885.USD","LU1978683503.SGD","LU0117841782.USD","09995","LU0823426480.USD","LU2097828474.EUR","LU0505663152.USD","06613","LU2148510915.USD","LU0320764755.SGD","LU1769817179.HKD","LU0700851271.USD","LU0499858438.USD","LU2477742899.HKD","LU0029875118.USD","LU0048580855.USD","LU0132412106.USD","LU2495084118.USD","LU0345775950.USD","LU0594300419.USD","LU1808992512.USD","LU0370786039.SGD","LU0254981946.USD","LU0106259558.USD","LU0169518387.USD","LU1770036033.HKD","LU0052750758.USD","LU0463099449.HKD","LU0124384867.USD","LU0149534421.HKD","LU1934453819.USD","IE00B3M56506.USD","LU0572944931.SGD","02186","BK1615","01093","BK1589","LU0210526637.USD","LU0405327494.USD","SG9999001689.USD","LU1956131251.USD","LU2045819591.USD","LU0049853897.USD","LU0348825331.USD","LU2399975544.HKD","LU1781817850.SGD","SG9999002463.SGD","LU1051769294.HKD","SG9999002828.SGD","01177","SG9999001093.SGD","LU1831875114.USD","BK1506","LU0235996351.USD","BK1535","LU0675040207.SGD","03908","BK1502","BK1523","LU0302445910.USD","LU0724618433.USD","LU2249611893.SGD","LU0634319403.HKD","LU1868838027.USD","LU0192582467.USD","BK1610","LU0348735423.USD","LU0708995583.HKD","LU1813983027.USD","LU2097828805.USD","LU1242518857.USD","LU1794554557.SGD","000333","BK1618","LU1064130708.USD","300433","01138","LU1997244956.HKD","LU0417516902.SGD","LU0165289439.USD","LU0499858602.USD","IE0003795394.USD","LU1868837565.USD","LU0823414551.USD","LU0106252389.USD","LU0149721374.USD","LU0501845795.SGD","LU1997245177.USD","LU2778985437.USD","LU1008478684.HKD","LU2506952337.HKD","LU1251922891.USD","LU1880383440.USD","LU0140636845.USD","LU2328871848.SGD","LU0405327148.USD","SG9999000459.SGD","LU0048575426.USD","LU1303224171.USD","LU2506951792.HKD","LU0509642566.USD","LU0043850808.USD","LU0455707207.USD","LU2298064838.USD","LU1961090484.USD","601995","LU1861214812.USD","LU0067412154.USD","LU2357125470.USD","LU1979443071.USD","SGXZ81163826.USD","LU0502904849.HKD","LU0823413587.USD","01898","LU0880133367.SGD","MIUmain","IE00BPRC5H50.USD","LU2275660780.HKD","LU2087589342.USD","LU0797268264.HKD","LU0469268626.HKD","601111","IE00B543WZ88.USD","LU0211977185.USD","LU1655091616.SGD","LU0651946864.USD","LU2153592121.USD","BK1521","LU0228659784.USD","LU0531971595.HKD","LU0072913022.USD","LU0543330483.HKD","LU2242644610.SGD","LU0651947912.USD","LU0828238088.HKD","LU0244354667.USD","LU1820825898.SGD","LU0828237940.HKD","LU0871576103.HKD","LU1960683339.HKD","LU1102505762.USD","LU0417516738.SGD","HK0000286598.CNH","LU2289578879.USD","LU2506952253.HKD","LU1880383366.USD","LU0269904917.USD","LU1770034418.SGD","LU1993786604.SGD","LU0516423174.USD","LU0588546209.SGD","LU0449515922.USD","LU1255011170.USD","SG9999014674.SGD","LU0516422952.EUR","LU0072462343.USD","LU1721428347.USD","LU0449509016.USD","LU0441854154.USD","BK1193","LU2449936058.SGD","BK4141","SG9999003461.SGD","LU1981816686.USD","LU1152091754.HKD","LU1242518931.SGD","LU0345776255.USD","LU0605514214.HKD","LU2476274720.SGD","IE00B29SXG58.USD","LU1188198961.HKD","LU0181495838.USD","LU1481107354.HKD","LU2097828714.EUR","HK0000181112.HKD","LU0823426308.USD","BK1607","LU1048588211.SGD","BK4588","002352","LU2097828557.USD","LU2294711473.HKD","LU0312595415.SGD","LU0823413660.USD","LU2580892862.HKD","LU1282648689.USD","600115","XIACY","81810","LU1939255532.USD","LU0164880469.USD","BK1149","LU0314109678.HKD","LU0214875030.USD","LU0561508036.HKD","LU0593848301.USD","LU0516422440.USD","LU0918141887.USD","LU0828237510.HKD","LU2257852520.SGD","03268","LU0320764599.SGD","LU1807302812.USD","LU0531970944.HKD","LU1719994722.HKD","688331","LU0164865239.USD","LU1023057109.AUD","SG9999000327.SGD","LU0048388663.USD","LU0823414478.USD","HK0000165453.HKD","IE0032431581.USD","LU2153591404.USD","LU0231483743.USD","IE00BZ199S13.USD","LU1769817096.USD","LU0823041008.USD","LU2039709279.SGD","BK4585","LU1997245094.SGD","LU1328277881.USD","LU0106959298.USD","06656","LU2424517915.HKD","LU2348774022.SGD","06936","HK0000181138.USD","LU1515016050.SGD","00753","IE0003851619.USD","LU0084288322.USD","LU0143863198.USD","LU0054450605.USD","LU0918141705.HKD","LU0359201885.HKD","LU2238339852.HKD","LU0823397285.USD","01810","BK4519","LU0327786744.USD","LU1152091168.USD","LU1861219969.SGD","03750","LU0326950275.SGD","LU0821914370.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627256069","title":"智通港股早知道 | 国家数据局拟探索词元交易等新型交易模式 央行上调部分银行境外贷款杠杆率","url":"https://stock-news.laohu8.com/highlight/detail?id=2627256069","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627256069?lang=zh_cn&edition=full","pubTime":"2026-04-16 07:41","pubTimestamp":1776296486,"startTime":"0","endTime":"0","summary":"探索词元交易等新型交易模式，构建以词元为基础，可量化、可定价的数据集价值体系。将进出口银行的境外贷款杠杆率由3上调至3.5。截至收盘，暗盘交易显示报价578港元，较招股价324.2港元上涨78.29%，每手100股，不计手续费，每手赚25380港元。归属于上市公司股东的净利润为207","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1116","LU1152091754.HKD","LU1960683339.HKD","LU1023057109.AUD","601995","BK1564","LU1152091168.USD","LU1807302812.USD","BK4588","01177","SBHMY","03750","LU2328871848.SGD","SG9999002828.SGD","LU0359202008.SGD","LU1008478684.HKD","BK1147","BK1610","LU0067412154.USD","BK1190","BK1161","300750","BK4585","08279","02245","BK1574","LU1993786604.SGD","688331","LU0359201612.USD","BK1501","LU0880133367.SGD","BK1516","BK1583","06656","LU1969619763.USD","09995","LU0359201885.HKD","03908"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627407539","title":"中国生物制药(01177)：维特柯妥拜单抗“CLDN18.2 ADC”一线胃及胃食管交界部腺癌III期临床试验完成首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2627407539","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627407539?lang=zh_cn&edition=full","pubTime":"2026-04-15 17:02","pubTimestamp":1776243779,"startTime":"0","endTime":"0","summary":"本研究为LM-302开展的第二项Ⅲ期临床试验，也是全球首个CLDN18.2 ADC药物采用无化疗方案用于胃癌一线治疗的Ⅲ期临床试验。这种“ADC+免疫”联合策略有望为CLDN18.2阳性胃癌患者带来更深度的肿瘤缓解。除本次启动的LM-302联合疗法用于一线治疗CLDN18.2阳性GC/GEJ的III期临床外，LM-302单药用于三线及以上CLDN18.2阳性GC/GEJ的III期临床研究已完成全部受试者入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428818.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","BK4231","IE00BZ08YT58.USD","BK1589","BK4134","ADC","IE00BZ08YS42.EUR","III","BK1191","01177","HK0000165453.HKD","IE00BZ08YR35.GBP","BK4080","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627404427","title":"港股收盘丨恒指涨0.29% 老铺黄金涨近7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627404427","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627404427?lang=zh_cn&edition=full","pubTime":"2026-04-15 16:12","pubTimestamp":1776240751,"startTime":"0","endTime":"0","summary":"恒生指数收涨0.29%，恒生科技指数涨1.23%。老铺黄金涨近7%，信达生物、中国生物制药涨逾5%，京东集团涨逾4%，阿里巴巴、携程集团、百度集团涨逾3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604153705909775.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604153705909775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09618","BK4588","MCHmain","01177","BABA","02833","SGXZ90724238.SGD","BK1544","513600","JD","TCOM","01801","HHImain","SG9999001051.SGD","09988","BK1227","MHImain","06181","BK4585","HSTECH","09961","SBHMY","HSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627963418","title":"大摩：升中国生物制药目标价至8.3港元 评级“增持”","url":"https://stock-news.laohu8.com/highlight/detail?id=2627963418","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627963418?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:12","pubTimestamp":1776150720,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　摩根士丹利发布研报称，更新对中国生物制药（01177）的风险回报评估。将集团2026至2028年销售额分别下降1%、3%、3%。预计今年公司收入将增长11%，受惠于来自赛诺菲的预付款，以及创新药和生物类似药录得逾20%的同比增长，足以抵销仿制药单位数字的跌幅。大摩将集团目标价由8港元上调至8.3港元，评级为“增持”。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：史丽君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-04-14/doc-inhunawe4132197.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","01177"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626578155","title":"中国生物制药(01177)：KYLO-11“LPA SIRNA”II期临床试验完成美国首例患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2626578155","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626578155?lang=zh_cn&edition=full","pubTime":"2026-04-10 06:09","pubTimestamp":1775772564,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团全资附属公司杭州赫吉亚生物医药有限公司自主研发的创新药Kylo-11“LPA siRNA”，其针对动脉粥样硬化性心血管疾病伴脂蛋白升高的II期临床试验，已完成美国首例患者入组。此前，该临床试验的中国部分已于2025年10月完成首例中国患者入组。Kylo-11是赫吉亚生物自主研发的靶向LPA基因的siRNA药物，具备全球同类最佳潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BZ08YT58.USD","BK1515","BK4233","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1589","BK1191","BK1521","LPA","HK0000165453.HKD","01177","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sinobiopharm.com","stockEarnings":[{"period":"1week","weight":-0.0533},{"period":"1month","weight":-0.0422},{"period":"3month","weight":-0.1433},{"period":"6month","weight":-0.1839},{"period":"1year","weight":0.4803},{"period":"ytd","weight":-0.0809}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物制药有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营。中药现代制剂及西药分部主要从事生产、销售及配销中药现代制剂及西药产品业务。投资分部主要从事长期投资业务。其他分部主要从事相关医疗及医院业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.434783,"avgChangeRate":0.008254},{"month":2,"riseRate":0.652174,"avgChangeRate":0.056687},{"month":3,"riseRate":0.565217,"avgChangeRate":0.045006},{"month":4,"riseRate":0.478261,"avgChangeRate":0.023215},{"month":5,"riseRate":0.727273,"avgChangeRate":0.043347},{"month":6,"riseRate":0.363636,"avgChangeRate":0.00957},{"month":7,"riseRate":0.636364,"avgChangeRate":0.047691},{"month":8,"riseRate":0.409091,"avgChangeRate":-0.010062},{"month":9,"riseRate":0.409091,"avgChangeRate":-0.015174},{"month":10,"riseRate":0.545455,"avgChangeRate":0.025184},{"month":11,"riseRate":0.5,"avgChangeRate":0.066781},{"month":12,"riseRate":0.409091,"avgChangeRate":-0.01175}],"exchange":"SEHK","name":"中国生物制药","nameEN":"SBP GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物制药,01177,中国生物制药股票,中国生物制药股票老虎,中国生物制药股票老虎国际,中国生物制药行情,中国生物制药股票行情,中国生物制药股价,中国生物制药股市,中国生物制药股票价格,中国生物制药股票交易,中国生物制药股票购买,中国生物制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物制药(01177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物制药(01177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}